Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Bowen Yang is reportedly leaving 'Saturday Night Live' after this week's episode - 2This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
- 3‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- 4How to see the Ursids, the final meteor shower of 2025
- 5Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- San Francisco sues 10 companies that make ultraprocessed food
- vote in favor of Your #1 kind of climate
- Hubble Space Telescope spies dusty debris from two cosmic collisions
- What's the new 'Knives Out' mystery about? Everything to know about 'Wake Up Dead Man,' including who's in the cast and what the reviews say.
- Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- Top 10 Moving Style Architects of the Year
- Discovery of ancient pleasure boat reveals Egypt's maritime history
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
